Asciminib is a novel inhibitor of ABL1and ABL2gene fusions in ALL but requires the ABL SH3 domain for efficacy

Details

Language :

English

ISSN :

00064971 and 15280020

Issue :

Preprints

Database :

Supplemental Index

Journal :

Blood

Publication Type :

Periodical

Accession number :

ejs66625465

Full Text :

https://doi.org/10.1182/blood.2024024776